Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Mark Hallett MD

Mark Hallett MD

Distinguished NIH Investigator Emeritus, National Institute of Neurological Disorders and Stroke, National Institutes of Health; Past-President, Functional Neurological Disorder Society, Bethesda, Maryland

Dr. Mark Hallett recently retired from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH), but he remains connected there as Distinguished NIH Investigator Emeritus. He is also the current Past-President of the Functional Neurological Disorder Society. His research work mainly deals with principles of motor control and the pathophysiology of movement disorders.

Dr. Hallett is a Past President of the International Federation of Clinical Neurophysiology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the International Parkinson and Movement Disorder Society, and a past Vice-President of the American Academy of Neurology. He is a past Editor-in-Chief of Clinical Neurophysiology and a past Associate Editor of Brain. He has served, and is now serving, on many editorial boards. He is the recipient of many honors and has delivered many named lectures worldwide.

Disclosures

  • Advisory boards: BrainsWay; VoxNeuro; QuantalX
  • Consultant: Janssen

Recent Contributions to PracticeUpdate:

  1. KMT2B-Related Disorders
  2. Identifying the Physiological Basis of Dyskinesias
  3. An Update on Misfolded Protein Targets for Alzheimer’s Disease
  4. Clinical Implications of New Data on MRgFUS Treatment for Parkinson's Disease
  5. New Data on Nilotinib as a Disease Modifying Drug Therapy for Parkinson’s Disease
  6. 2020 Top Stories in Neurology: When Does Parkinson Disease Begin and What is Parkinson Disease Anyway?
  7. Brain Network Function and Clinical Neurologic Disorders
  8. New Data on Calcium Channel Modulator for Essential Tremor
  9. Istradefylline as an Adjunct to Levodopa in Parkinson’s Disease
  10. Determination of Brain Death/Death by Neurologic Criteria

Most Read This Week

Recently Updated